NeoGenomics, Inc.
12701 Commonwealth Drive
Suite 9
Fort Myers
Florida
33913
United States
Tel: 239-768-0600
Fax: 239-768-0711
Website: http://www.neogenomics.org/
Email: info@neogenomics.org
266 articles about NeoGenomics, Inc.
-
NeoGenomics To Participate In The Bank of America 2021 Health Care Conference
5/10/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank of America 2021 Health Care Conference, on Wednesday, May 12, 2021 at 4:15pm ET.
-
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
5/5/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that it has agreed to acquire Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England.
-
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
5/5/2021
First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed the acquisition of Trapelo Health in April
-
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
4/19/2021
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type.
-
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
4/13/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the 20 th Annual Needham Virtual Healthcare Conference 2021, on Thursday, April 15, 2021 at 11:00am ET.
-
NeoGenomics Agrees to Acquire Trapelo Health
3/24/2021
NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Intervention Insights, Inc. d/b/a Trapelo Health, an Information Technology company focused on precision oncology.
-
Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study
3/16/2021
Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels
-
NeoGenomics and Elevation Oncology Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study
3/16/2021
Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics Advanced Gene Fusion Panels
-
NeoGenomics To Participate In The Virtual Raymond James 42nd Annual Institutional Investors Conference
3/1/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chief Financial Officer Kathryn McKenzie and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual Raymond James 42 nd Annual Institutional Investors Conference 2021, on Wednesday, March 3, 2021 at 10:50am ET.
-
NeoGenomics To Participate In The Virtual 10th Annual SVB Leerink Global Healthcare Conference
2/25/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual 10 th Annual SVB Leerink Global Healthcare Conference 2021, on Friday, February 26, 2021
-
NeoGenomics Reports 18% Revenue Growth to $126 Million in the Fourth Quarter
2/24/2021
Fourth-Quarter 2020 Results and Highlights: Consolidated revenue increased 18% to $126 million Clinical Services revenue increased 14% to $107 million Pharma Services revenue increased 43% to $19 million
-
Mallon announced his resignation from Ironwood earlier this month to take on a new leadership opportunity and “pursue multiple passions.”
-
NeoGenomics Announces CEO Succession
2/24/2021
Mark Mallon named CEO effective April 2021; Douglas M. VanOort will retire as CEO and transition to executive chairman of the board of directors
-
NeoGenomics to Participate in the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference
2/16/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference 2021
-
NeoGenomics Schedules its Fourth Quarter and Full Year 2020 Earnings Release for February 24, 2021
2/5/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021.
-
Parexel and NeoGenomics Announce Strategic Collaboration in Precision Medicine to Improve Study Designs and Accelerate Patient Matching in Oncology Clinical Trials
2/4/2021
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, and NeoGenomics, Inc.(NASDAQ:NEO), a leading provider of cancer-focused genetic testing services announced a strategic partnership
-
NeoGenomics and Tempus Join the Access to Comprehensive Genomic Profiling Coalition
2/2/2021
The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of NeoGenomics, Inc. (NASDAQ: NEO) and Tempus to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.
-
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
1/6/2021
The size of the notes offering was increased from the previously announced amount. The offerings of the shares and the notes are expected to close on or about January 11, 2021, subject to the satisfaction of customary closing conditions.
-
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
1/5/2021
NeoGenomics, Inc. (NASDAQ:NEO) a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced that it has commenced proposed underwritten public offerings of approximately $200,000,000 of newly issued shares of common stock and $250,000,000 aggregate principal amount of convertible senior notes due 2028
-
NeoGenomics To Virtually Participate In The 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, Dr. Lawrence Weiss, Chief Medical Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the virtual 39 th Annual J.P. Morgan Healthcare Conference 2